APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Factor Xa Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oral Factor Xa Inhibitors Market Outlook and Growth Opportunities 2026

29 December 2025203 pages

Choose your research edition.

Industry ResearchOral Factor Xa Inhibitors Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Factor Xa Inhibitors Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Oral Factor Xa Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Factor Xa Inhibitors Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Factor Xa Inhibitors Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Oral Factor Xa Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oral Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oral Factor Xa Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oral Factor Xa Inhibitors market include Accord Healthcare, Apotex, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Lupin, Mylan and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral Factor Xa Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Factor Xa Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Factor Xa Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Factor Xa Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral Factor Xa Inhibitors Segment by Company

Accord Healthcare

Apotex

Bayer

Bristol Myers Squibb

Daiichi Sankyo

Janssen Pharmaceuticals

Lupin

Mylan

Pfizer

Zydus

HEC Pharma

Hansoh Pharma

Huahai Pharmaceutical

Shanghai Huilun Pharmaceutical

Qilu Pharmaceutical

Cspc Ouyi Pharmaceutical

Yangtze River Pharmaceutical

Zhejiang Hisun Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Oral Factor Xa Inhibitors Segment by Type

Edoxaban

Rivaroxaban

Apixaban

Oral Factor Xa Inhibitors Segment by Application

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Other

Oral Factor Xa Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oral Factor Xa Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Oral Factor Xa Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oral Factor Xa Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze Oral Factor Xa Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Factor Xa Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Factor Xa Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Factor Xa Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral Factor Xa Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oral Factor Xa Inhibitors industry.

Chapter 3: Detailed analysis of Oral Factor Xa Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Oral Factor Xa Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Oral Factor Xa Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oral Factor Xa Inhibitors Industry Trends Table 2. Oral Factor Xa Inhibitors Industry Drivers Table 3. Oral Factor Xa Inhibitors Industry Opportunities and Challenges Table 4. Oral Factor Xa Inhibitors Industry Restraints Table 5. Global Oral Factor Xa Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oral Factor Xa Inhibitors Revenue Share by Company (2021-2026) Table 7. Global Oral Factor Xa Inhibitors Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Oral Factor Xa Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global Oral Factor Xa Inhibitors Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Oral Factor Xa Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global Oral Factor Xa Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global Oral Factor Xa Inhibitors Company, Product Type & Application Table 13. Global Oral Factor Xa Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral Factor Xa Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Edoxaban Table 18. Significant Companies of Rivaroxaban Table 19. Significant Companies of Apixaban Table 20. Global Oral Factor Xa Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Oral Factor Xa Inhibitors Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Oral Factor Xa Inhibitors Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Oral Factor Xa Inhibitors Sales Volume Share by Type (2021-2026) Table 24. Global Oral Factor Xa Inhibitors Sales Volume Share by Type (2027-2032) Table 25. Global Oral Factor Xa Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Oral Factor Xa Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Oral Factor Xa Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Oral Factor Xa Inhibitors Sales Value Share by Type (2021-2026) Table 29. Global Oral Factor Xa Inhibitors Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Pulmonary Embolism Table 31. Significant Companies of Deep Vein Thrombosis Table 32. Significant Companies of Atrial Fibrillation Table 33. Significant Companies of Other Table 34. Global Oral Factor Xa Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Oral Factor Xa Inhibitors Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Oral Factor Xa Inhibitors Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Oral Factor Xa Inhibitors Sales Volume Share by Application (2021-2026) Table 38. Global Oral Factor Xa Inhibitors Sales Volume Share by Application (2027-2032) Table 39. Global Oral Factor Xa Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Oral Factor Xa Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Oral Factor Xa Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Oral Factor Xa Inhibitors Sales Value Share by Application (2021-2026) Table 43. Global Oral Factor Xa Inhibitors Sales Value Share by Application (2027-2032) Table 44. Global Oral Factor Xa Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Oral Factor Xa Inhibitors Sales by Region (2021-2026) & (K Units) Table 46. Global Oral Factor Xa Inhibitors Sales Market Share by Region (2021-2026) Table 47. Global Oral Factor Xa Inhibitors Sales by Region (2027-2032) & (K Units) Table 48. Global Oral Factor Xa Inhibitors Sales Market Share by Region (2027-2032) Table 49. Global Oral Factor Xa Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Oral Factor Xa Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Oral Factor Xa Inhibitors Sales Value Share by Region (2021-2026) Table 52. Global Oral Factor Xa Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Oral Factor Xa Inhibitors Sales Value Share by Region (2027-2032) Table 54. Global Oral Factor Xa Inhibitors Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Oral Factor Xa Inhibitors Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Oral Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Oral Factor Xa Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 59. Global Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2026) Table 60. Global Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 61. Global Oral Factor Xa Inhibitors Sales Market Share by Country (2027-2032) Table 62. Global Oral Factor Xa Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Oral Factor Xa Inhibitors Sales Value Market Share by Country (2021-2026) Table 64. Global Oral Factor Xa Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Oral Factor Xa Inhibitors Sales Value Market Share by Country (2027-2032) Table 66. Accord Healthcare Company Information Table 67. Accord Healthcare Business Overview Table 68. Accord Healthcare Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Accord Healthcare Oral Factor Xa Inhibitors Product Portfolio Table 70. Accord Healthcare Recent Development Table 71. Apotex Company Information Table 72. Apotex Business Overview Table 73. Apotex Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Apotex Oral Factor Xa Inhibitors Product Portfolio Table 75. Apotex Recent Development Table 76. Bayer Company Information Table 77. Bayer Business Overview Table 78. Bayer Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Bayer Oral Factor Xa Inhibitors Product Portfolio Table 80. Bayer Recent Development Table 81. Bristol Myers Squibb Company Information Table 82. Bristol Myers Squibb Business Overview Table 83. Bristol Myers Squibb Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolio Table 85. Bristol Myers Squibb Recent Development Table 86. Daiichi Sankyo Company Information Table 87. Daiichi Sankyo Business Overview Table 88. Daiichi Sankyo Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolio Table 90. Daiichi Sankyo Recent Development Table 91. Janssen Pharmaceuticals Company Information Table 92. Janssen Pharmaceuticals Business Overview Table 93. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolio Table 95. Janssen Pharmaceuticals Recent Development Table 96. Lupin Company Information Table 97. Lupin Business Overview Table 98. Lupin Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Lupin Oral Factor Xa Inhibitors Product Portfolio Table 100. Lupin Recent Development Table 101. Mylan Company Information Table 102. Mylan Business Overview Table 103. Mylan Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Mylan Oral Factor Xa Inhibitors Product Portfolio Table 105. Mylan Recent Development Table 106. Pfizer Company Information Table 107. Pfizer Business Overview Table 108. Pfizer Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Pfizer Oral Factor Xa Inhibitors Product Portfolio Table 110. Pfizer Recent Development Table 111. Zydus Company Information Table 112. Zydus Business Overview Table 113. Zydus Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Zydus Oral Factor Xa Inhibitors Product Portfolio Table 115. Zydus Recent Development Table 116. HEC Pharma Company Information Table 117. HEC Pharma Business Overview Table 118. HEC Pharma Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. HEC Pharma Oral Factor Xa Inhibitors Product Portfolio Table 120. HEC Pharma Recent Development Table 121. Hansoh Pharma Company Information Table 122. Hansoh Pharma Business Overview Table 123. Hansoh Pharma Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolio Table 125. Hansoh Pharma Recent Development Table 126. Huahai Pharmaceutical Company Information Table 127. Huahai Pharmaceutical Business Overview Table 128. Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 130. Huahai Pharmaceutical Recent Development Table 131. Shanghai Huilun Pharmaceutical Company Information Table 132. Shanghai Huilun Pharmaceutical Business Overview Table 133. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 135. Shanghai Huilun Pharmaceutical Recent Development Table 136. Qilu Pharmaceutical Company Information Table 137. Qilu Pharmaceutical Business Overview Table 138. Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 140. Qilu Pharmaceutical Recent Development Table 141. Cspc Ouyi Pharmaceutical Company Information Table 142. Cspc Ouyi Pharmaceutical Business Overview Table 143. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 145. Cspc Ouyi Pharmaceutical Recent Development Table 146. Yangtze River Pharmaceutical Company Information Table 147. Yangtze River Pharmaceutical Business Overview Table 148. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 150. Yangtze River Pharmaceutical Recent Development Table 151. Zhejiang Hisun Pharmaceutical Company Information Table 152. Zhejiang Hisun Pharmaceutical Business Overview Table 153. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 155. Zhejiang Hisun Pharmaceutical Recent Development Table 156. Chia Tai Tianqing Pharmaceutical Company Information Table 157. Chia Tai Tianqing Pharmaceutical Business Overview Table 158. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 160. Chia Tai Tianqing Pharmaceutical Recent Development Table 161. Key Raw Materials Table 162. Raw Materials Key Suppliers Table 163. Oral Factor Xa Inhibitors Distributors List Table 164. Oral Factor Xa Inhibitors Customers List Table 165. Research Programs/Design for This Report Table 166. Authors List of This Report Table 167. Secondary Sources Table 168. Primary Sources List of Figures Figure 1. Oral Factor Xa Inhibitors Product Image Figure 2. Global Oral Factor Xa Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Factor Xa Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global Oral Factor Xa Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Oral Factor Xa Inhibitors Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Oral Factor Xa Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Edoxaban Image Figure 10. Rivaroxaban Image Figure 11. Apixaban Image Figure 12. Global Oral Factor Xa Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Oral Factor Xa Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Oral Factor Xa Inhibitors Sales Volume Share by Type (2021-2032) Figure 15. Global Oral Factor Xa Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Oral Factor Xa Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Oral Factor Xa Inhibitors Sales Value Share by Type (2021-2032) Figure 18. Pulmonary Embolism Image Figure 19. Deep Vein Thrombosis Image Figure 20. Atrial Fibrillation Image Figure 21. Other Image Figure 22. Global Oral Factor Xa Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Oral Factor Xa Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Oral Factor Xa Inhibitors Sales Volume Share by Application (2021-2032) Figure 25. Global Oral Factor Xa Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Oral Factor Xa Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Oral Factor Xa Inhibitors Sales Value Share by Application (2021-2032) Figure 28. Global Oral Factor Xa Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Oral Factor Xa Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Oral Factor Xa Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Oral Factor Xa Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Oral Factor Xa Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 33. North America Oral Factor Xa Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Oral Factor Xa Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Oral Factor Xa Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Oral Factor Xa Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Oral Factor Xa Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Oral Factor Xa Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 39. South America Oral Factor Xa Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Oral Factor Xa Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Oral Factor Xa Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Oral Factor Xa Inhibitors Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Oral Factor Xa Inhibitors Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Edoxaban
  • Rivaroxaban
  • Apixaban
Applications
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Other
Companies covered
  • Accord Healthcare
  • Apotex
  • Bayer
  • Bristol Myers Squibb
  • Daiichi Sankyo
  • Janssen Pharmaceuticals
  • Lupin
  • Mylan
  • Pfizer
  • Zydus
  • HEC Pharma
  • Hansoh Pharma
  • Huahai Pharmaceutical
  • Shanghai Huilun Pharmaceutical
  • Qilu Pharmaceutical
  • Cspc Ouyi Pharmaceutical
  • Yangtze River Pharmaceutical
  • Zhejiang Hisun Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oral Factor Xa Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global Oral Factor Xa Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global Oral Factor Xa Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Oral Factor Xa Inhibitors Market Dynamics
  1. 2.1 Oral Factor Xa Inhibitors Industry Trends
  2. 2.2 Oral Factor Xa Inhibitors Industry Drivers
  3. 2.3 Oral Factor Xa Inhibitors Industry Opportunities and Challenges
  4. 2.4 Oral Factor Xa Inhibitors Industry Restraints
3 Oral Factor Xa Inhibitors Market by Company
  1. 3.1 Global Oral Factor Xa Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global Oral Factor Xa Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global Oral Factor Xa Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global Oral Factor Xa Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global Oral Factor Xa Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global Oral Factor Xa Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global Oral Factor Xa Inhibitors Company Product Type and Application
  8. 3.8 Global Oral Factor Xa Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Oral Factor Xa Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Oral Factor Xa Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Oral Factor Xa Inhibitors Market by Type
  1. 4.1 Oral Factor Xa Inhibitors Type Introduction
  2. 4.1.1 Edoxaban
  3. 4.1.2 Rivaroxaban
  4. 4.1.3 Apixaban
  5. 4.2 Global Oral Factor Xa Inhibitors Sales Volume by Type
  6. 4.2.1 Global Oral Factor Xa Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Oral Factor Xa Inhibitors Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Oral Factor Xa Inhibitors Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Oral Factor Xa Inhibitors Sales Value by Type
  10. 4.3.1 Global Oral Factor Xa Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Oral Factor Xa Inhibitors Sales Value by Type (2021-2032)
  12. 4.3.3 Global Oral Factor Xa Inhibitors Sales Value Share by Type (2021-2032)
5 Oral Factor Xa Inhibitors Market by Application
  1. 5.1 Oral Factor Xa Inhibitors Application Introduction
  2. 5.1.1 Pulmonary Embolism
  3. 5.1.2 Deep Vein Thrombosis
  4. 5.1.3 Atrial Fibrillation
  5. 5.1.4 Other
  6. 5.2 Global Oral Factor Xa Inhibitors Sales Volume by Application
  7. 5.2.1 Global Oral Factor Xa Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Oral Factor Xa Inhibitors Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Oral Factor Xa Inhibitors Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Oral Factor Xa Inhibitors Sales Value by Application
  11. 5.3.1 Global Oral Factor Xa Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Oral Factor Xa Inhibitors Sales Value by Application (2021-2032)
  13. 5.3.3 Global Oral Factor Xa Inhibitors Sales Value Share by Application (2021-2032)
6 Oral Factor Xa Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global Oral Factor Xa Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Factor Xa Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Oral Factor Xa Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global Oral Factor Xa Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global Oral Factor Xa Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Oral Factor Xa Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global Oral Factor Xa Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global Oral Factor Xa Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global Oral Factor Xa Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Oral Factor Xa Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America Oral Factor Xa Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Oral Factor Xa Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe Oral Factor Xa Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Oral Factor Xa Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Oral Factor Xa Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Oral Factor Xa Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America Oral Factor Xa Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Oral Factor Xa Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Oral Factor Xa Inhibitors Sales Value Share by Country, 2025 VS 2032
7 Oral Factor Xa Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global Oral Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oral Factor Xa Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Oral Factor Xa Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global Oral Factor Xa Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global Oral Factor Xa Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global Oral Factor Xa Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global Oral Factor Xa Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global Oral Factor Xa Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Oral Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Oral Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Oral Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Accord Healthcare
  2. 8.1.1 Accord Healthcare Company Information
  3. 8.1.2 Accord Healthcare Business Overview
  4. 8.1.3 Accord Healthcare Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Accord Healthcare Oral Factor Xa Inhibitors Product Portfolio
  6. 8.1.5 Accord Healthcare Recent Developments
  7. 8.2 Apotex
  8. 8.2.1 Apotex Company Information
  9. 8.2.2 Apotex Business Overview
  10. 8.2.3 Apotex Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Apotex Oral Factor Xa Inhibitors Product Portfolio
  12. 8.2.5 Apotex Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Oral Factor Xa Inhibitors Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 Bristol Myers Squibb
  20. 8.4.1 Bristol Myers Squibb Company Information
  21. 8.4.2 Bristol Myers Squibb Business Overview
  22. 8.4.3 Bristol Myers Squibb Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolio
  24. 8.4.5 Bristol Myers Squibb Recent Developments
  25. 8.5 Daiichi Sankyo
  26. 8.5.1 Daiichi Sankyo Company Information
  27. 8.5.2 Daiichi Sankyo Business Overview
  28. 8.5.3 Daiichi Sankyo Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolio
  30. 8.5.5 Daiichi Sankyo Recent Developments
  31. 8.6 Janssen Pharmaceuticals
  32. 8.6.1 Janssen Pharmaceuticals Company Information
  33. 8.6.2 Janssen Pharmaceuticals Business Overview
  34. 8.6.3 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolio
  36. 8.6.5 Janssen Pharmaceuticals Recent Developments
  37. 8.7 Lupin
  38. 8.7.1 Lupin Company Information
  39. 8.7.2 Lupin Business Overview
  40. 8.7.3 Lupin Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lupin Oral Factor Xa Inhibitors Product Portfolio
  42. 8.7.5 Lupin Recent Developments
  43. 8.8 Mylan
  44. 8.8.1 Mylan Company Information
  45. 8.8.2 Mylan Business Overview
  46. 8.8.3 Mylan Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Mylan Oral Factor Xa Inhibitors Product Portfolio
  48. 8.8.5 Mylan Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Oral Factor Xa Inhibitors Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Zydus
  56. 8.10.1 Zydus Company Information
  57. 8.10.2 Zydus Business Overview
  58. 8.10.3 Zydus Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Zydus Oral Factor Xa Inhibitors Product Portfolio
  60. 8.10.5 Zydus Recent Developments
  61. 8.11 HEC Pharma
  62. 8.11.1 HEC Pharma Company Information
  63. 8.11.2 HEC Pharma Business Overview
  64. 8.11.3 HEC Pharma Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 HEC Pharma Oral Factor Xa Inhibitors Product Portfolio
  66. 8.11.5 HEC Pharma Recent Developments
  67. 8.12 Hansoh Pharma
  68. 8.12.1 Hansoh Pharma Company Information
  69. 8.12.2 Hansoh Pharma Business Overview
  70. 8.12.3 Hansoh Pharma Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolio
  72. 8.12.5 Hansoh Pharma Recent Developments
  73. 8.13 Huahai Pharmaceutical
  74. 8.13.1 Huahai Pharmaceutical Company Information
  75. 8.13.2 Huahai Pharmaceutical Business Overview
  76. 8.13.3 Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  78. 8.13.5 Huahai Pharmaceutical Recent Developments
  79. 8.14 Shanghai Huilun Pharmaceutical
  80. 8.14.1 Shanghai Huilun Pharmaceutical Company Information
  81. 8.14.2 Shanghai Huilun Pharmaceutical Business Overview
  82. 8.14.3 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  84. 8.14.5 Shanghai Huilun Pharmaceutical Recent Developments
  85. 8.15 Qilu Pharmaceutical
  86. 8.15.1 Qilu Pharmaceutical Company Information
  87. 8.15.2 Qilu Pharmaceutical Business Overview
  88. 8.15.3 Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  90. 8.15.5 Qilu Pharmaceutical Recent Developments
  91. 8.16 Cspc Ouyi Pharmaceutical
  92. 8.16.1 Cspc Ouyi Pharmaceutical Company Information
  93. 8.16.2 Cspc Ouyi Pharmaceutical Business Overview
  94. 8.16.3 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  96. 8.16.5 Cspc Ouyi Pharmaceutical Recent Developments
  97. 8.17 Yangtze River Pharmaceutical
  98. 8.17.1 Yangtze River Pharmaceutical Company Information
  99. 8.17.2 Yangtze River Pharmaceutical Business Overview
  100. 8.17.3 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  102. 8.17.5 Yangtze River Pharmaceutical Recent Developments
  103. 8.18 Zhejiang Hisun Pharmaceutical
  104. 8.18.1 Zhejiang Hisun Pharmaceutical Company Information
  105. 8.18.2 Zhejiang Hisun Pharmaceutical Business Overview
  106. 8.18.3 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  108. 8.18.5 Zhejiang Hisun Pharmaceutical Recent Developments
  109. 8.19 Chia Tai Tianqing Pharmaceutical
  110. 8.19.1 Chia Tai Tianqing Pharmaceutical Company Information
  111. 8.19.2 Chia Tai Tianqing Pharmaceutical Business Overview
  112. 8.19.3 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  114. 8.19.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral Factor Xa Inhibitors Value Chain Analysis
  2. 9.1.1 Oral Factor Xa Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral Factor Xa Inhibitors Sales Mode & Process
  6. 9.2 Oral Factor Xa Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral Factor Xa Inhibitors Distributors
  9. 9.2.3 Oral Factor Xa Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst